Becton Dickinson
Becton, Dickinson and Company (NYSE: BDX), known as BD, is a global medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Its customers include healthcare institutions, clinicians, laboratories, life science researchers, pharmaceutical… From the company’s description.
In fiscal 2025, Becton Dickinson reported revenue of $21.84B, up 8.2% from fiscal 2024, and net income of $1.68B. Its operating margin was 11.8%, and operations generated $3.43B in cash. Over the twelve months to Jun 30, 2026, revenue was $20.07B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Becton Dickinson does
In the company’s own words
Becton, Dickinson and Company (NYSE: BDX), known as BD, is a global medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Its customers include healthcare institutions, clinicians, laboratories, life science researchers, pharmaceutical and biotechnology companies, public health agencies and consumers. For the fiscal year ended September 30, 2025, BD operated through three worldwide segments: BD Medical, which supplies medication delivery and management systems, prefillable drug delivery products and patient monitoring technologies; BD Life Sciences, which provides specimen collection, diagnostic testing and cell analysis products; and BD Interventional, which offers surgical, vascular, urology and critical care products. Effective October 1, 2025, BD reorganized into five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. It employs approximately 72,000 associates across 61 countries. BD completed its Diabetes Care separation into Embecta in 2022 and has agreed to combine its Biosciences and Diagnostic Solutions businesses with Waters Corporation. Its website is www.bd.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- FRANKLIN LAKES, NJ
- Fiscal year end
- September
- CIK
- 10795
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Becton Dickinson — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Becton Dickinson · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Becton Dickinson’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Becton Dickinson’s bonds, as funds hold them
Funds report holding 20 issues of Becton Dickinson’s debt, $1.06B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.86%, maturing 2026 to 2050.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Becton Dickinson and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Becton Dickinson's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Becton Dickinson's last four quarterly filings that the numbers alone won't show?”